(MENAFNEditorial)
Cystic fibrosis also known as mucoviscidosis is a genetically inherited disease. The primary symptoms of cystic fibrosis include high salt content in the sweat breathing difficulties secretion of abnormally viscous mucus respiratory complications difficulties related to digestion and growth anomalies. Cystic fibrosis is one of the most common genetic disorders observed in Caucasian children. Rare diseases are those that affect less than 5 patients per 10000 as defined in the EU by Rare Disease UK. Cystic fibrosis is therefore classified under rare diseases. The incidence of cystic fibrosis varies between populations. It is significantly less common in Asian and African populations compared to Caucasians (people from Europe North America and Australasia) with a marked difference between each country in those regions. Precise data regarding the prevalence of cystic fibrosis in Europe is not available but it is estimated to be 1 in 8000-10000 individuals. Cystic fibrosis is a chronic disease and is usually progressive in nature. The onset of cystic fibrosis typically occurs in early childhood or rarely at birth. The principal manifestations of cystic fibrosis in patients are chronic bronchitis pancreatic insufficiency adolescent diabetes pancreatitis male sterility and very rarely intestinal obstruction or liver cirrhosis. The mortality and morbidity of patients are dependent on the degree of bronchopulmonary involvement.
Full Report Details at
- http://www.fastmr.com/prod/957478_cystic_fibrosis_market_in_europe_20152019.aspx?afid=101
TechNavio's analysts forecast the Cystic Fibrosis market in Europe to grow at a CAGR of 35.10 percent over the period 2014-2019.
Covered in this Report
This report covers the present scenario and the growth prospects of the Cystic Fibrosis market in Europe for the period 2015-2019. To calculate the market size the report considers the revenue generated from the sales of various generic and branded therapies used in the treatment of cystic fibrosis including:
* Small Molecules
* Biologics
TechNavio's report Cystic Fibrosis Market in Europe 2015-2019 has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers data from Europe; it also covers the market landscape of the Cystic Fibrosis market in Europe and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
Key Vendors
* Actavis
* F. Hoffmann-La Roche
* Gilead Sciences
* Novartis
* Vertex Pharmaceuticals
Other Prominent Vendors
* Abbott
* Anthera Pharmaceuticals
* Arcturus Therapeutics
* Boehringer Ingelheim
* Chiesi Farmaceutici
* Corbus Pharmaceuticals
* Genzyme
* Insmed
* Johnson & Johnson
* Merck Sharp & Dohme
* Neovii Biotech
* Novo Nordisk
* PharmaSwiss
* Pharmaxis
* Proteostasis Therapeutics
* PTC Therapeutics
* United Medical
* Venus Remedies
Market Driver
* Unmet Needs
* For a full detailed list view our report
Market Challenge
* High Cost of Treatments
* For a full detailed list view our report
Market Trend
* Rise in Public Awareness
* For a full detailed list view our report
Key Questions Answered in this Report
* What will the market size be in 2019 and what will the growth rate be?
* What are the key market trends?
* What is driving this market?
* What are the challenges to market growth?
* Who are the key vendors in this market space?
Research methodology is based on extensive primary and secondary research. Primary research includes in-depth interviews with industry experts vendors resellers and customers. Secondary research includes Technavio Platform industry publications company reports news articles analyst reports trade associations and the data published by Government agencies.
Companies Mentioned in this Report: Actavis F. Hoffmann-La Roche Gilead Sciences Novartis Vertex Pharmaceuticals Abbott Anthera Pharmaceuticals Arcturus Therapeutics Boehringer Ingelheim Chiesi Farmaceutici Corbus Pharmaceuticals Genzyme Insmed Johnson & Johnson Merck Sharp & Dohme Neovii Biotech Novo Nordisk PharmaSwiss Pharmaxis Proteostasis Therapeutics PTC Therapeutics United Medical Venus Remedies
Partial Table of Contents:
01. Executive Summary
02. List of Abbreviations
03. Scope of the Report
03.1 Market Overview
03.2 Product Offerings
04. Market Research Methodology
04.1 Market Research Process
04.2 Research Methodology
05. Product Profiles
05.1.1 Zenpep
05.1.2 Colomycin/Colobreathe
05.1.3 Pulmozyme
05.1.4 Cayston
05.1.5 TOBI/TOBI Podhaler
05.1.6 Kalydeco
06. Introduction
07. Disease Overview
07.1 Understanding the Disease
07.2 Pathophysiology
07.3 Epidemiology
07.3.1 Global
07.3.2 UK
07.4 Diagnosis
07.4.1 Carrier Testing
07.4.2 Antenatal Testing
07.4.3 Newborn Screening
07.4.4 Other Tests
07.5 Manifestations of Cystic Fibrosis
07.6 Economic Burden
08. Pipeline Portfolio
09. Market Landscape
09.1 Market Overview
09.2 Market Size and Forecast
09.3 Five Forces Analysis
10. Segmentation of Cystic Fibrosis Market in Europe by Molecule Type
10.1 Biologics
10.1.1 Enzymes
10.2 Small Molecules
10.2.1 CFTR Modulators
10.2.2 Antibiotics
11. Segmentation of Cystic Fibrosis Market in Europe by Route of Administration
11.1 Oral
11.2 Parenteral
11.3 Topical
12. Segmentation of Cystic Fibrosis Market in Europe by Dosage Form
12.1 Solid
12.2 Liquid
13. Key Leading Countries
13.1 UK
13.2 France
13.3 Italy
13.4 Germany
13.5 Spain
14. Buying Criteria
15. Market Growth Drivers
16. Drivers and their Impact
17. Market Challenges
18. Impact of Drivers and Challenges
19. Market Trends
20. Trends and their Impact
21. Vendor Landscape
21.1 Competitive Scenario
21.1.1 Key News
21.1.2 Mergers and Acquisitions
21.2 Market Share Analysis 2014
21.2.1 Actavis
21.2.2 F. Hoffmann-La Roche
21.2.3 Gilead Sciences
21.2.4 Novartis
21.2.5 Vertex Pharmaceuticals
21.3 Other and Future Prominent Vendors
22. Key Vendor Analysis
22.1 Actavis
22.1.1 Key Facts
22.1.2 Business Description
22.1.3 Business Segmentation
22.1.4 Business Segmentation by Revenue 2012 and 2013
22.1.5 Sales by Geography
22.1.6 Business Strategy
22.1.7 Key Information
22.1.8 SWOT Analysis
22.2 F. Hoffmann-La Roche
22.2.1 Key Facts
22.2.2 Business Overview
22.2.3 Business Segmentation
Full Table of Contents is available at:
-- http://www.fastmr.com/prod/957478_cystic_fibrosis_market_in_europe_20152019.aspx?dt=t&afid=101
About Fast Market Research
Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts we provide quick and easy access to the best competitive intelligence available. Our unbiased expert staff is always available to help you find the right research to fit your requirements and your budget.
For more information about these or related research reports please visit our website at http://www.fastmr.com or call us at 1.800.844.8156 (1.413.485.7001 Int'l)
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.